Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
Microsoft
MSFT
|
+$7.54B |
| 2 |
Apple
AAPL
|
+$5.11B |
| 3 |
Amazon
AMZN
|
+$2.93B |
| 4 |
UnitedHealth
UNH
|
+$2.83B |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$2.75B |
Top Sells
| 1 |
ZEN
ZENDESK INC
ZEN
|
+$330M |
| 2 |
Snap
SNAP
|
+$321M |
| 3 |
Twilio
TWLO
|
+$309M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$156M |
| 5 |
AVLR
Avalara, Inc.
AVLR
|
+$154M |
Sector Composition
| 1 | Technology | 29.71% |
| 2 | Healthcare | 21.23% |
| 3 | Financials | 11.2% |
| 4 | Consumer Discretionary | 10.46% |
| 5 | Industrials | 9.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
451
PotlatchDeltic
PCH
$3.21B
| $66.6M | 0.02% |
1,622,816
+515,554
| +47% | +$21.2M |
|
|
DICE
452
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $66.4M | 0.02% |
3,271,296
+1,561,976
| +91% | +$31.7M |
|
453
Criteo
CRTO
$1.23B
| $66.3M | 0.02% |
2,450,332
+1,184,149
| +94% | +$32M |
|
454
Mondelez International
MDLZ
$79.6B
| $65.8M | 0.02% |
1,200,972
+544,685
| +83% | +$29.9M |
|
|
EGRX
455
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $65.5M | 0.02% |
2,479,558
+1,042,244
| +73% | +$27.5M |
|
456
UBS Group
UBS
$127B
| $65.3M | 0.02% |
4,438,028
+2,147,710
| +94% | +$31.6M |
|
457
First Horizon
FHN
$11.4B
| $64.9M | 0.02% |
2,833,652
+1,232,443
| +77% | +$28.2M |
|
|
HEES
458
DELISTED
H&E Equipment Services
HEES
| $64.7M | 0.02% |
2,283,110
+1,127,366
| +98% | +$31.9M |
|
459
Phillips Edison & Co
PECO
$4.46B
| $64.7M | 0.02% |
2,304,990
+519,414
| +29% | +$14.6M |
|
460
Vistra
VST
$70.1B
| $64.6M | 0.02% |
3,077,044
+1,572,992
| +105% | +$33M |
|
461
Portillo's
PTLO
$446M
| $64.2M | 0.02% |
3,260,842
+2,159,090
| +196% | +$42.5M |
|
462
FLEX LNG
FLNG
$1.36B
| $64.1M | 0.02% |
2,015,166
+475,893
| +31% | +$15.1M |
|
|
CLVT.PRA
463
DELISTED
Clarivate Plc 5.25% Series A Mandatory Convertible Preferred Shares
CLVT.PRA
| $63.9M | 0.02% |
1,507,554
+906,577
| +151% | +$38.4M |
|
464
Fate Therapeutics
FATE
$114M
| $63.9M | 0.02% |
2,849,452
+1,413,939
| +98% | +$31.7M |
|
465
Upwork
UPWK
$2.09B
| $63M | 0.02% |
4,625,736
+2,315,525
| +100% | +$31.5M |
|
466
Ambarella
AMBA
$3.59B
| $62.6M | 0.02% |
1,114,668
+542,747
| +95% | +$30.5M |
|
467
Alcon
ALC
$39.2B
| $62.3M | 0.02% |
1,057,182
+531,295
| +101% | +$31.3M |
|
468
COPT Defense Properties
CDP
$3.46B
| $61.4M | 0.02% |
2,643,454
+1,092,463
| +70% | +$25.4M |
|
469
Collegium Pharmaceutical
COLL
$1.19B
| $61.4M | 0.02% |
3,831,996
+1,622,993
| +73% | +$26M |
|
470
SBA Communications
SBAC
$20.8B
| $60.9M | 0.02% |
213,916
+104,636
| +96% | +$29.8M |
|
471
International Flavors & Fragrances
IFF
$16.5B
| $60.9M | 0.02% |
670,414
-59,380
| -8% | -$5.39M |
|
|
CNH
472
CNH Industrial
CNH
$14.2B
| $60.7M | 0.02% |
5,334,426
+1,642,290
| +44% | +$18.7M |
|
473
Moderna
MRNA
$9.58B
| $60.4M | 0.02% |
510,688
+232,552
| +84% | +$27.5M |
|
474
Sea Limited
SE
$113B
| $60.2M | 0.02% |
1,074,186
+171,108
| +19% | +$9.59M |
|
475
Wallbox
WBX
$65.5M
| $60.2M | 0.02% |
381,670
+260,408
| +215% | +$41M |
|